1 mg
Trade Name
Remollio
Film-coated tablet
Request Type
New Registration
Drug Type
Generic(Multisource) Drug
Approval Date
SFDA Approved Use
Chronic thromboembolic pulmonary hypertension (CTEPH)
Riociguat is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with
• inoperable CTEPH,
• persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity
Pulmonary arterial hypertension (PAH)
Riociguat, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.
Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.
Riociguat is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with
• inoperable CTEPH,
• persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity
Pulmonary arterial hypertension (PAH)
Riociguat, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.
Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.